Introduction to Intellectual Property Class of Sept. 20 2003.

Slides:



Advertisements
Similar presentations
Technology Center 1600 Training on Writing Rejections Under 35 U.S.C. § 103.
Advertisements

Welcome to the FICPI ABC Conference © Birch, Stewart, Kolasch & Birch, LLP KSR v. Teleflex: U.S. Supreme Court Decision Raises Patentability Standard.
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
1 Examination Standard of Inventive Step in Taiwan Tony C. H. Lin Patent Attorney APAA Taiwan Group Lee and Li, Attorneys-at-Law November 18, 2007 in Adelaide.
1 35 U.S.C. § 112, first paragraph and the Wands Analysis Remy Yucel, SPE 1636 (571)
Patent, Trademark, Copyright, and Enforcement - Law and Policy November 5-8, 2007 United States Patent and Trademark Office Global Intellectual Property.
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
Gene Therapy: Overcoming Enablement Rejections Karen M. Hauda Supervisory Patent Examiner Art Unit 1632 (703)
Claim Interpretation By: Michael A. Leonard II and Jared T. Olson.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
FITZPATRICK, CELLA, HARPER & SCINTO © 2008 | 1 Obviousness Under 35 U.S.C. §103 in the United States Bruce C. Haas, Esq.
Determining Obviousness under 35 USC 103 in view of KSR International Co. v. Teleflex TC3600 Business Methods January 2008.
Biopiracy Biopiracy is defined as, “the illegal appropriation of life – micro-organisms, plants and animals (including humans) and the traditional knowledge.
Nonobviousness Patent Law Prof. Merges –
Vs. Miguel Chan UC Berkeley IEOR 190G March 2009.
Graham v John Deere Patent Law. Justice Tom Clark ( )
Intellectual Property
Intellectual Property Boston College Law School March 5, 2008 Patent – Nonobviousness 2.
102/103 Prior Art Patent Law Sources of 102/103 Art 35 USC 103: “differences between subject matter sought to be patented and the prior art”
Intellectual Property Boston College Law School March 3, 2008 Patent - Nonobviousness.
Patent Overview by Jeff Woller. Why have Patents? Patents make some people rich – but, does that seem like something the government should protect? Do.
Intellectual Property Boston College Law School February 16, 2009 Patent – Novelty.
Examination Issues: Immunology Yvonne (Bonnie) Eyler Quality Assurance Specialist Technology Center 1600 USPTO (571)
Nonobviousness II Intro to IP – Prof Merges
Utility Model Protection Rahul Dutta Patent Attorney Intellectual Property Lab melting ideas into property
Stem Cells Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Stem Cells — Origin Examination of Stem Cell Claims — Statutes — Sample Claims.
1 Current Issues in Intellectual Property 112 S. West Street Alexandria, Virginia
Determining Obviousness Under 35 U.S.C. § 103 After KSR v. Teleflex
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Applicant’s Reply: Applicant’s Reply: A TC1600 WORKSHOP A Workshop to Help Us Better Respond to Applicant’s Reply after FAOM A Workshop to Help Us Better.
PATENTS Elements of Patentability Victor H. Bouganim WCL, American University.
Routine Optimization Jean Witz, tQAS, TC
Overcoming Prior Art References Non-Enabling Prior Art References Gary Kunz SPE Art Unit 1616.
Obviousness II Class Notes: February 11, 2003 Law 677 | Patent Law | Spring 2003 Professor Wagner.
35 U.S.C. 112, Second Paragraph Examination Memorandum Robert Clarke Director, Office of Patent Legal Administration United States Patent and Trademark.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
Intellectual Property Law © 2007 IBM Corporation EUPACO 2 – The European Patent Conference 16 May 2007 Patent Quality Roger Burt IBM Europe.
New Sections 102 & 103 (b) Conditions for Patentability- (1) IN GENERAL- Section 102 of title 35, United States Code, is amended to read as follows: -`Sec.
6.1 Chapter 6 Patents © 2003 by West Legal Studies in Business/A Division of Thomson Learning.
Overview Validity of patent hinges on novelty, utility, and non-obviousness Utility generally not an issue Pre-suit investigation focuses on infringement,
1 Examination Guidelines Update: Developments in the Obviousness Inquiry After KSR v.Teleflex.
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
Patents IV Nonobviousness
Claims, Anticipation, and Obviousness Kathleen Kahler Fonda Legal Advisor, Office of Patent Legal Administration July 30, 2010.
1 Examination Guidelines Update: Developments in the Obviousness Inquiry After KSR v.Teleflex Biotech/Chem/Pharma Customer Partnership Meeting December.
Claims and Determining Scope of Protection -Introduction Nov. 9, 2014 APAA Patents Committee Penang Malaysia Kay Konishi Co-chair of APAA Patents Committee.
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. TC 1600 Biotech/Chem/Pharma.
Olek Pawlowski IEOR 190 Spring 2009 UC Berkeley Explaining the basic concepts of the landmark Supreme Court patent case of KSR vs. Teleflex and specifically.
Nonobviousness II: More on Nonobviousness The Scope & Content of the Prior Art Law 677 | Patent Law | Spring 2002 Administrative: (1)reminder: Federal.
Obviousness I Class Notes: February 6, 2003 Law 677 | Patent Law | Spring 2003 Professor Wagner.
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. Kathleen Kahler Fonda Legal.
Patents II Disclosure Requirements Class 12 Notes Law 507 | Intellectual Property | Spring 2004 Professor Wagner.
This Webcast Will Begin Shortly If you have any technical problems with the Webcast or the streaming audio, please contact us via at:
BLW 360 – January 27, 2015 Jonathan LA Phillips
© 2011 Barnes & Thornburg LLP. All Rights Reserved. This page, and all information on it, is the property of Barnes & Thornburg LLP which may not be reproduced,
© 2015 Waller Lansden Dortch & Davis, LLP. All Rights Reserved. Ready to Patent? Value and Risk Considerations Nicolo Davidson.
Introduction to Intellectual Property Class of Sept
Unless otherwise noted, the content of this course material is licensed under a Creative Commons Attribution 3.0 License.
Processes Which Employ Non-Obvious Products
Keiko K. Takagi Sughrue Mion, PLLC
Developing approaches to learning skills Step 1Objective strand: Approaches to learning skill: Step 2Explicit learning experience: Step 3Implicit learning.
Patents IV Nonobviousness
Law 677 | Patent Law | Spring 2003
Prosecution Luncheon Patent March 2017
Patents II Disclosure Requirements
Wisdom of the Board Ex parte PTAB Decisions Show Effective Arguments to Overcome an Obviousness Rejection Trent Ostler The content is exclusively the.
Stem Cells Peter Paras, Jr.
Update and Practical Considerations
Advanced Patent Law Institute Palo Alto
Presentation transcript:

Introduction to Intellectual Property Class of Sept

Non-Obviousness S. 103 Purpose? Interpretation Graham v. John Deere

Graham v. John Deere 4 factors

Graham v. John Deere 4 factors: 1. scope and content of prior art 2. differences between prior art and claims at issue 3. level of ordinary skill in pertinent art 4. secondary considerations

COMBINING REFERENCES In re Vaeck (Fed. Cir. 1991) In re Demiczak (Fed. Cir. 1999)

COMBINING REFERENCES Explicit or implicit suggestion to those of ordinary skill in art in prior art reference(s) Reasonable expectation of success Avoid hindsight

PROBLEM 3-9 In re Gorman, 933 F.2d 982 (Fed. Cir. 1991)

DISCLOSURE REQUIREMENTS S. 112 ENABLEMENT DISCLOSURE BEST MODE